SYMBYX Biome

What SYMBYX Biome does

SYMBYX Biome is an Australian medical-device company that designs, develops, and sells at-home photobiomodulation (PBM) laser devices targeting Parkinson's disease, chronic pain and inflammation, brain health, and gut health. Its core technology applies red (620-750nm) and near-infrared (780-1000nm) light to stimulate cellular mitochondrial function and ATP production, with the company's flagship PDCare laser using a proprietary Abdomen-Neck Protocol to address Parkinson's symptoms via the gut-brain axis. The product portfolio includes the ARTG-listed, CE-marked PDCare, DuoCare 904, PhysioCare, and DermaCare handheld lasers, the SYMBYX Neuro transcranial wellness helmet, and the ProSeries professional-grade unit, all designed in Australia with manufacturing in Sweden and Korea.

The company operates a direct-to-consumer e-commerce model, selling devices globally through its Shopify storefront with regional sub-sites for Australia, the US, and the UK, supported by free express international shipping and a dedicated clinical support function. Pricing is quote-based with UK VAT-relief eligibility for qualifying chronic-condition patients, and a one-year manufacturing warranty is included. The go-to-market combines content marketing (blog, webinars, YouTube, 25,000+ email subscribers), earned media (Forbes, The Guardian), conference presence (World Parkinson's Congress, Parkinson's Australia), and partnerships with more than nine patient advocacy organizations, supplemented by an extensive clinical evidence base built through RCTs with Flinders University, Sydney Adventist Hospital, Mater Research, University of Leeds, and others, published in BMC Neurology, Journal of Clinical Medicine, and THE LANCET eClinicalMedicine.

SYMBYX was founded in 2020 in Sydney by Dr Wayne Markman (CEO, former Credit Suisse director) and Peter Carre (Chairman, former Garvan Institute commercialization director), with a board that includes Harvard alumni and the founder of Zapata Computing. The company is privately held, raised a Series A in May 2021, and operates from Neutral Bay, Australia with a UK regional office in London, employing 11-50 people and serving 2,500+ customers at a 4.9/5 satisfaction rating.

Name

SYMBYX Biome

Legal name

SYMBYX Pty Ltd

Website

https://symbyxbiome.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

SYMBYX Biome is an Australian medtech company that designs and sells at-home photobiomodulation laser devices, primarily serving individuals with Parkinson's disease, chronic pain, and brain health concerns through direct-to-consumer e-commerce with global shipping.

Ownership category

akta.pro rank

Product category

Photobiomodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices) (CRACAQAL)

akta.pro secondary industry

Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• Photobiomodulation devices
• Low-level laser therapy
• Medical laser equipment
• At-home therapy devices
• Light therapy devices

Headquarters

HQ city

Neutral Bay

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations, Infrastructure

Revenue model

1. Light Therapy Device Sales: SYMBYX generates revenue primarily through the sale of medical-grade photobiomodulation devices including PDCare (Parkinson's), SYMBYX Neuro (brain health), DuoCare 904, PhysioCare, DermaCare, and ProSeries. Devices are sold directly through their e-commerce platform with global shipping.
2. Clinical Support Services: Ongoing clinical support provided to customers using their devices. This support service enhances customer retention and device utilization, contributing indirectly to revenue through customer satisfaction and referrals.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels8 records

Core offering

SYMBYX Biome designs, develops, and sells at-home medical-grade photobiomodulation (PBM) laser devices for individuals with Parkinson's disease, chronic pain, inflammation, fibromyalgia, and brain health concerns. Its products include the PDCare Laser (ARTG-listed, CE-marked for Parkinson's symptom reduction), SYMBYX Neuro transcranial helmet, DuoCare 904, PhysioCare, DermaCare, and the ProSeries clinical device, sold direct-to-consumer via the company's e-commerce platform with bundled clinical support.

Product overview

SYMBYX Biome offers a portfolio of five distinct at-home photobiomodulation (PBM) laser devices and one wellness helmet, all based on light therapy technology. The core product lineup consists of: PDCare Laser (ARTG-listed medical device for Parkinson's symptoms), SYMBYX Neuro (wellness helmet for brain health), DuoCare 904 (rechargeable 904nm laser for pain/inflammation), PhysioCare (battery-operated pain/inflammation laser), DermaCare (635nm red laser), and ProSeries (professional-grade laser). Devices are designed and developed in Australia, with manufacturing in Sweden and Korea. The company positions these as complementary therapies alongside standard medical care, with ongoing clinical support provided to customers.

Differentiator

Problem solved

Functional benefit

Brands

• PDCare: Handheld laser device for reducing Parkinson's disease symptoms. ARTG-listed and CE-marked medical device.
• SYMBYX Neuro
• DuoCare 904
• PhysioCare
• DermaCare
• ProSeries

Products and services

• PDCare Laser A handheld, battery-operated photobiomodulation (PBM) laser device for at-home use, CE-marked and ARTG-listed as a complementary therapy for reduction of Parkinson's disease symptoms using the Abdomen-Neck Protocol. Targets the gut and back of neck with red and infrared light wavelengths.
• SYMBYX Neuro (Wellness Helmet) An infrared and red-light therapy wellness helmet designed and developed in Australia, providing 24-minute automated transcranial treatment cycles targeting posterior brain regions. Clinically tested for brain health support and as an adjunct to standard Parkinson's care; classified as a general wellness device.
• DuoCare 904 A medical-grade rechargeable infrared laser device delivering photobiomodulation at 904 nanometres, treating pain and inflammatory issues at four different tissue depths. Marketed as treating pain/inflammation 3x faster than PhysioCare.
• PhysioCare Laser A medical-grade laser designed for home use, specifically approved for the reduction of fibromyalgia symptoms and pain/inflammation. Battery-operated (6 x AAA), making it portable and accessible.
• DermaCare A 635nm red laser device for dermatological applications and skin health, part of SYMBYX's handheld laser product line.
• ProSeries A professional-grade laser therapy device in the SYMBYX product lineup, requiring safety glasses during use and designed for clinical practitioners rather than at-home consumers.

Quantifiable outcome

• Approximately 70% of participants saw moderate-to-large clinical improvements in motor symptoms (facial expression, upper limb movement, gait, tremor) in SYMBYX Neuro clinical trial
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• University of LeedscoreStrategic or Co-development Partner · 4 March 2025Strategic research collaboration with Professors Lijing Ke (Plant Biochemistry and Nutrition) and Kieran Tuohy (Energy Metabolism and Microbiome) to investigate how light therapy may change gut health. Study will employ co-culture cell models and in vitro models of human colonic microbiota. Results expected 2026. This research explains the mechanistic basis of light therapy's effects on the gut-brain axis and Parkinson's symptoms.
• Flinders University, AustraliacoreStrategic or Co-development PartnerResearch partner for clinical trials examining the effectiveness of the SYMBYX system in treating non-motor symptoms of Parkinson's disease. Conducting randomized controlled trial with 36 participants assessing whether the SYMBYX system is viable for non-motor symptoms.
• Sydney Adventist Hospital, AustraliacoreStrategic or Co-development PartnerDr Geoffrey Herkes serves as San Hospital Research Director and Research Partner. Site of triple-blinded randomized-controlled trial using SYMBYX Neuro helmet for Parkinson's disease. Published results in Journal of Clinical Medicine.
• Mater Research Hospital, BrisbanecoreStrategic or Co-development PartnerClinical trial examining effectiveness of SYMBYX laser light in reducing symptoms associated with Inflammatory Bowel Disease (IBD) in young adults. Study evaluating efficacy as a potential therapeutic option for managing IBD symptoms. Dr Liisa Laakso and Dr Tatjana Ewais are research partners.
• NICM Health Research Institute, AustraliacoreStrategic or Co-development PartnerDr Brian Bicknell serves as research partner. Contributing to research on photobiomodulation therapy mechanisms and applications.
• University of Grenoble, FrancecoreStrategic or Co-development PartnerDr John Mitrofanis serves as research partner, contributing expertise in photobiomodulation research.
• Macquarie University, AustraliacoreStrategic or Co-development PartnerProfessor Hosen Kiat (MD, Cardiologist) serves as Scientific Advisor. Contributes expertise in cardiac health and light therapy applications.
• Saltmarche Associates, CanadacoreStrategic or Co-development PartnerCo-principal investigators led by Anita Saltmarche (RN, MPH) for Canadian clinical trial assessing effectiveness of SYMBYX system in treating motor and non-motor symptoms of Parkinson's disease. 60 participants in randomized controlled trial.
• Gaitway Neurophysio, CanadacoreStrategic or Co-development PartnerOrla Hares (Neurophysiotherapist) serves as co-principal investigator alongside Saltmarche Associates for Canadian clinical trial.
• Parkinson's SAminorStrategic or Co-development PartnerCollaborative partner for Adelaide clinical trial examining SYMBYX system effectiveness for non-motor symptoms of Parkinson's disease.
• Boston University, USAminorStrategic or Co-development PartnerProfessor Margaret Naeser serves as Research Partner, contributing expertise in photobiomodulation research from Boston.
• Newcastle University, UKminorStrategic or Co-development PartnerDr Daniel Johnstone serves as Scientific Advisor, contributing to research on photobiomodulation mechanisms.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Aspen Laser: Aspen Laser offers Class IV PBM laser therapy systems for clinical practitioners and at-home pain/inflammation treatment, overlapping SYMBYX's pain/inflammation franchise.
• Vielight: Vielight makes transcranial photobiomodulation devices (including the Vielight Neuro) targeting brain health and Parkinson's; closest direct peer to SYMBYX's Neuro helmet and PDCare positioning.
• Thor Photomedicine: Thor manufactures clinical-grade photobiomodulation/laser therapy equipment used for pain, inflammation, and neurological conditions; shares SYMBYX's low-level laser/photobiomodulation core technology and medical customer base.
• Multi Radiance Medical: Multi Radiance Medical produces PBM/laser therapy devices for pain management, rehab, and clinical use; directly competes in the LLLT medical-device category that SYMBYX addresses with PDCare, DuoCare, and PhysioCare.
• Cala Health: Cala Health makes wearable neurostimulation devices (TAPS) FDA-cleared for essential tremor and Parkinson's-related tremor, targeting the same Parkinson's population as SYMBYX with a non-pharmaceutical, at-home therapy.

Broad incumbents

• LiteCure: LiteCure, part of DJO, markets Class IV therapy lasers for medical and rehabilitation use across a broad portfolio; competes more broadly in the PBM/therapeutic-laser market rather than SYMBYX's neurological niche.
• Joovv: Joovv sells consumer red-light therapy panels for general wellness, recovery and skin; comparable on the underlying red/infrared light technology but positioned more for wellness than SYMBYX's regulated medical devices.
• Celluma: Celluma manufactures FDA-cleared LED light therapy devices for pain, skin and musculoskeletal conditions; overlaps with SYMBYX's pain/inflammation and DermaCare dermatology offerings on the consumer-clinic interface.

Emerging players

• MitoQ: MitoQ (NZ-origin) markets mitochondria-targeted supplements positioned around cellular energy (ATP) and Parkinson's/chronic disease support; adjacent rather than directly competing, but aligned with SYMBYX's mitochondrial mechanism narrative.
• ElectroCore: ElectroCore makes non-invasive vagus nerve stimulation (nVNS) devices for neurological and inflammatory conditions, pursuing similar non-pharma neurological indications to SYMBYX but with electrical stimulation rather than photobiomodulation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SYMBYXbiome
• YouTubeyoutube.com/channel/UCC_i0xmSB0_UC8t9EkeXMcg
• Facebookfacebook.com/symbyxbiome
• LinkedInau.linkedin.com/company/symbyxbiome
• Instagraminstagram.com/symbyx
• Pinterestpinterest.com.au/sally34460210
• TikToktiktok.com/@symbyxbiome

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SYMBYX Biome